Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
A biomarker is an indicator that can be accurately measured as a signal for normal biological function, pathogenic pathways, or drug response to therapeutic drug mediation. Biological markers are usually molecularly shaped. Biological markers occur in various bodily functions, including diagnosis and prognosis of disease, prediction and calculation of treatment response, and safety assessment. These biomarkers are developed and approved for use in drug development, and to support the approval of drug products.
The biomarkers used to treat cancer are referred to as cancer biomarkers. They are helpful in making specific diagnoses. Cancer biomarkers also identify and determine whether tumors are of primary or metastatic origin. A biomarker for cancer can be a molecule secreted by a tumor or a specific body response to the presence of cancer. Biomarkers of human prostate, breast, ovarian and lung cancers, as well as those of heart disease, arthritis, asthma and cystic fibrosis, have been examined. Biological markers can determine the accuracy of the diagnosis, can be linked to other investigations to suspect the type of cancer.
Detection stages of clinical support and translated biomarkers are used to identify the effect of compound on organs or tissues before the clinical effect is demonstrated. It can be classified into three general classes: biomarkers for disease, target biomarkers and Mechanism biomarkers. A biomarker for translation is based on whether it can be noticeable, measurable and ultimately it can be qualified or verified.
Cardiovascular disease (CVD) remains the leading factor in the world. The identification of traditional risk factors such as age, hypertension, diabetes and smoking improved the primary prevention of CVD. Heart markers are measured biomarkers to evaluate heart function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an increase in the level of the heart marker. Cardiac biomarkers are elements that release into the blood when the heart is injured or strained. A heart marker is used to identify and stratify proliferation of patients with chest pain and suspected acute coronary syndrome (ACS). These markers include enzymes, hormones and proteins. Cardiac biomarkers have emerged as an essential tool in cardiology over the past fifty years, namely for primary and secondary prevention, diagnosis and treatment of acute myocardial infarction (AMI), and diagnosis and stratification of the risk of heart failure.
Molecular biomarkers defined as biomarkers that can be discovered through basic and widely accepted platforms such as genomics and proteomics. Apart from genomics and proteomics platforms, biomarker analysis techniques such as metabolomics, lipidomic, glycaemic are most commonly used as biomarker detection techniques. Molecular biomarkers are classified into pathological biomarkers, nucleic acid biomarkers, insilco biomarkers, glycoprotein biomarkers and bio-imaging markers based on their structure and function. These biomarkers can be tested for non-abnormally collected biological fluids, such as blood or serum.
Drug Discovery with biomarkers is used exclusively for diagnosis and monitoring of patients in clinical trials. Biological markers improve the success rates of drug development programs and thus accelerate the availability of advanced therapies. Biomarker development is a multi-step and repetitive process starting with the discovery of biomarkers in infectious diseases. In this session, an analytical validation phase of biomarker development, pharmacogenomics, functional proteomics, biological analytical validation method, pharmacokinetic models will be developed.
Bio markers are used as diagnostic tools for accurately identifying disease states, for identifying high-risk and predictable individuals, effectively treating patients with illnesses, and are also targeted to specific biological sites. Advances in genomics, proteomics, metabolomics and bioinformatics have made it possible to discover several biomarkers.
Blood biomarkers are involved in multiple sclerosis (MS) studies, autoimmune dysfunction of the central nervous system. There is a significant need not met by biomarkers to assess prognosis, response to treatment or potential complications in treatment. There are several limitations in the process of detecting and validating a good biomarker, such as the pathophysiological complexity of multiple sclerosis and the technical difficulties of a global standard of methods for sampling, processing, and retaining biological samples.
Biological markers are major tools in drug development and drug research. Biological markers have been recognized for making the drug development process more efficient and becoming an essential part of pharmacology and drug research. Several biomarkers are expected to eventually be transferred to the clinical laboratory. Biological markers demonstrate drug-dose-response relationships between changes in biomarker, onset of injury, and severity of injury consistent with the progression of the injury.
Genomics-related biomarkers measure changes in the amount or nature of nucleic acids. DNA-based biomarkers include copy number variation, mutations and epigenetic modification. Biological markers based on RNA expression include quantification of mRNA, microRNA and long non-coding RNA expression. The serum consists of several small size peptides, as a result of various cellular activities, called a serum proteome. Proteomics is widely used in the study of a wide range of medical fields including drug development and biomarker discovery. By coordinating with other advanced genomics and bioinformatics techniques, proteomics has the broad contribution to identifying biomarkers and revolutionizing the drug development process.
Neurology deals with the diagnosis and treatment of central and peripheral nervous system disease and is one of the typical disciplines in which personalized medicine has become an important part of clinical trials. Various issues in neurology regarding personalized medicine and diagnostic, prognostic and predictive biomarkers should be discussed. The role of biomarkers and personalized medicine in neuro-oncology is becoming extremely important. The actual state of knowledge should be discussed in several areas of neurology.
The use of biomarkers and diagnostic assessments continues to evolve with more uses and the introduction of more effective sensitivity tests. These tests are powerful clinical care tools that approach different therapeutic areas such as oncology, immunology, cardiology and endocrinology. Recent advances in biosensors to detect biomarkers in cancer treatment.
Biomarkers in health and disorders are concerned about the promising findings in a pediatric autism spectrum disorder survey. The researchers were able to use cerebral magnetic resonance imaging (MRI) to assess cortical and cerebrovascular development, in infants aged 6-12 months at risk of ASD with ASD affected children, who will have ASD up to 24 months. While this study requires further validation in a larger group of 15 out of 106 high-risk subjects who eventually developed ASD, it does talk about the enormous and unmet medical need of biomarkers for neural and psychiatric disorders. Co-morbidity with other psychiatric disorders is also uncommon and contributes to dizzying heterogeneity in possible diagnoses. Clinical biomarkers can help transcend these limitations.
Bio markers play an important role in the prognosis and diagnosis of various cardiovascular and neurological diseases. Diseases that are deadly from age have possible treatment and easy diagnosis with advances in biomarkers using various diagnostic methods and imaging technologies. Cardiac biomarkers and neuro-biomarkers have revolutionized disease diagnosis and prognosis. These biomarkers are also used in many other non-cancerous diseases. Some of the important ones are Alzheimer's disease, cardiovascular disease, Huntington's disease, degenerative disease, diabetes.
Bio-imaging markers are the class of biomarkers that allow earlier detection of disease compared to molecular biomarkers, which optimizes the translational research in drug discovery and researchers under cancer images in the market. Some of the image-based biomarkers are X-ray, computed tomography (CT), positron emission tomography (PET), single emission computed tomography (SPECT), and magnetic resonance imaging (MRI).
Digital biomarkers are commonly referred to as a digital device diagnosis that can provide clinical information as significant digital data. It can predict the physiological and behavioural studies of the patient's condition which determine what a healthy normal stage of disease and future health outcomes. It can be called a self-diagnostic device that can be wearable, portable, transplantable and digestible depending on diagnosis and condition.
Biological or genetic tests are a set of tests that look for the molecular signs of health so that doctors can best treat them. Biological markers, a basis for accurate oncology, are very important in the management of oesophageal, breast and lung cancers. Testing practices are intensively assessed, affecting the quality of diagnosis and affecting pathologists, oncologists and patients. Advances in biomarker testing are primarily in the fields of cancer that have been divided into chromosomes, gene tests and biochemical tests. Micro-RNA biomarkers, number of other clinical biomarkers that have emerged in the latest study have opened the way for wider biomarker testing.
Biomarkers are used to detect the presence of a disease or condition and to detect individuals with a subtype of disease. Diagnostic biomarkers allow the development of specific cancer screening programs (cellular and molecular pathology). Therapeutic biomarkers deal with a huge variety of therapeutic treatments for cardiovascular disease, rarity, infectious disease, hereditary disease.